7DW8-5 Glycolipid Activation of NKT Cells for Variant Respiratory Viruses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and prophylactic therapies are inadequate against rapidly mutating SARS-COV-2 variants, and there is a lack of effective treatments for COVID-19 and other virus-induced respiratory infections.
Innovation Solution
Administration of a pharmaceutical composition containing a therapeutically effective amount of a glycolipid, such as 7DW8-5 or α-GalCer, to activate natural killer T (NKT) cells, induce an innate immune response, and increase cytokine secretion, particularly interferon-γ, to combat respiratory infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccines are used, then immunity is provided against original SARS-COV-2 strain, but they become ineffective against rapidly mutating viral variants
Solution Approach 1:
The patent activates the body's own innate immune system (NKT cells and interferon production) to provide defense against viral variants, rather than relying on externally administered vaccines that target specific strains. The immune system serves itself by producing broad-spectrum antiviral responses through glycolipid activation.
Solution Approach 2:
The glycolipid-based therapy provides universal protection against multiple viral variants and different respiratory viruses (SARS-COV-2 variants, influenza, RSV) by activating conserved innate immune pathways that recognize common viral patterns, rather than strain-specific adaptive immunity.
2Ease of operation
If conventional treatments are used, then symptomatic relief is provided, but there is a lack of effective therapies that reduce viral load
Solution Approach 1:
The patent replaces conventional symptomatic treatment approaches with an immunomodulatory mechanism that directly targets viral replication by activating immune cells to produce antiviral cytokines, thereby reducing viral load rather than merely managing symptoms.
3Measurement precision
If adaptive immune response is relied upon, then specific viral targeting is achieved, but response time is delayed and effectiveness against variants is reduced
Solution Approach 1:
The patent activates the innate immune system in advance to provide immediate antiviral defense upon viral exposure, before adaptive immune responses can develop. The pre-activated NKT cells and interferon production create a rapid first line of defense against viral infection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The glycolipid activates immune cells, including iNKT, CD8+ T, and CD4+ T cells, enhancing the immune response and reducing viral load in respiratory infections, including SARS-COV-2 variants like Omicron and Delta, and other respiratory viruses like influenza and RSV.
Implementation Method 1
7DW8-5 is a glycolipid that binds to CD1d and activates innate T cells, known as natural killer T (NKT) cells, through their T cell receptors
Implementation Method 2
Upon activation, these cells can secrete cytokines. For example, activated CD8+ T cells can induce cell death of virus-infected cells via the production of cytokines, such as interferon-γ (1). Additionally, interferon-γ can induce an antiviral state in uninfected cells (1)
Implementation Method 3
Interferon-γ can induce an antiviral state in uninfected cells, thereby limiting viral spread and severity of disease
Data Source
AI summary
The subject matter described herein relates to methods of zNKT cell activation by the 7DW8-5 glycolipid.